Dialysis patients get a closer look at a diabetes Drug's hidden potential
NCT ID NCT07527390
First seen Apr 22, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study looks at how the drug canagliflozin moves through the body of people on dialysis. Researchers want to see if it reaches tissues like the heart and blood vessels, even when kidneys are not working well. Ten adults on dialysis will receive a special radioactive version of the drug and have PET scans to track it. The goal is to learn whether this drug might offer benefits beyond the kidney, not to treat or cure kidney disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIALYSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9713 GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.